H.C. Wainwright raised the firm’s price target on Kazia Therapeutics (KZIA) to $18 from $13 and keeps a Buy rating on the shares. The company presented “encourating” results from its Phase 1 study of paxalisib for the treatment of triple-negative breast cancer, the analyst tells investors in a research note.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on KZIA:
- Kazia Therapeutics Unveils Promising Paxalisib Data at Breast Cancer Symposium
- Kazia Therapeutics announces presentation from paxalisib studies
- Kazia Therapeutics Secures $46.5 Million Through Private Placement to Address Nasdaq Compliance
- Kazia Therapeutics Secures $50 Million in Private Placement to Advance Cancer Drug Development
- Kazia Therapeutics trading resumes